Table 3 Outcomes of the patent certification of ANDAs in China
From: Characteristics and outcomes of the drug patent linkage system in China
P1 | P2 | P3 | P4 | Total | |
|---|---|---|---|---|---|
ANDA, no. (%) | 4303(85.1) | 226(4.5) | 309(6.1) | 220(4.3) | 5058 |
Year | |||||
2021 (Second half), no. (%) | 809(84.7) | 26(2.7) | 71(7.5) | 49(5.1) | 955 |
2022, no. (%) | 1905(84.3) | 105(4.6) | 144(6.4) | 107(4.7) | 2261 |
2023 (First half), no. (%) | 1589(86.3) | 95(5.1) | 94(5.1) | 64(3.5) | 1842 |
Registration classification | |||||
Class 3, no. (%) | 1775(98.7) | 2(0.1) | 10(0.6) | 11(0.6) | 1798 |
Class 4, no. (%) | 2350(77.1) | 210(6.9) | 291(9.6) | 196(6.4) | 3047 |
Class 5.2, no. (%) | 178(83.6) | 14(6.6) | 8(3.8) | 13(6.1) | 213 |